Clinical and Biological Significance of <i<ESR1</i< Gene Alteration and Estrogen Receptors Isoforms Expression in Breast Cancer Patients

The amplification of estrogen receptor alpha (ERα) encoded by the <i<ESR1</i< gene has been described as having a prognostic role in breast cancer patients. However, increased dosage of the <i<ESR1</i< gene (tested by real-time PCR) is also observed in ER-negative breast canc...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Anna Nagel [verfasserIn] Jolanta Szade [verfasserIn] Mariola Iliszko [verfasserIn] Julia Elzanowska [verfasserIn] Marzena Welnicka-Jaskiewicz [verfasserIn] Jaroslaw Skokowski [verfasserIn] Grzegorz Stasilojc [verfasserIn] Jacek Bigda [verfasserIn] Rafal Sadej [verfasserIn] Anna Zaczek [verfasserIn] Aleksandra Markiewicz [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2019

Schlagwörter:	breast cancer estrogen receptor ERα36, ERα66, gene amplification prognostic factor

Übergeordnetes Werk:	In: International Journal of Molecular Sciences - MDPI AG, 2003, 20(2019), 8, p 1881
Übergeordnetes Werk:	volume:20 ; year:2019 ; number:8, p 1881

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.3390/ijms20081881

Katalog-ID:	DOAJ045603391

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ045603391
003	DE-627
005	20230308093747.0
007	cr uuu---uuuuu
008	230227s2019 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.3390/ijms20081881 \|2 doi
035			\|a (DE-627)DOAJ045603391
035			\|a (DE-599)DOAJ366d1ba6c63f4fc5a4a15f556e226d90
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a QH301-705.5
050		0	\|a QD1-999
100	0		\|a Anna Nagel \|e verfasserin \|4 aut
245	1	0	\|a Clinical and Biological Significance of <i<ESR1</i< Gene Alteration and Estrogen Receptors Isoforms Expression in Breast Cancer Patients
264		1	\|c 2019
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a The amplification of estrogen receptor alpha (ERα) encoded by the <i<ESR1</i< gene has been described as having a prognostic role in breast cancer patients. However, increased dosage of the <i<ESR1</i< gene (tested by real-time PCR) is also observed in ER-negative breast cancers, which might suggest the expression of alternative isoforms of ERα (other than classical ERα of 66 kDa). In the current work, we have investigated the <i<ESR1</i< gene dosage in 402 primary breast cancer patients as well as the expression of ERα isoforms—ERα66 and ERα36—on mRNA and protein levels. The obtained results were correlated with clinicopathological data of the patients. Results showed that increased <i<ESR1</i< gene dosage is not related to <i<ESR1</i< gene amplification measured by fluorescent in situ hybridization (FISH), but it correlates with the decreased expression of <i<ERα66</i< isoform (<i<p</i< = 0.01). Interestingly, the short ER isoform <i<ERα36</i< was expressed in samples with increased <i<ESR1</i< gene dosage, suggesting that genomic aberration might influence the expression of that particular isoform. Similarly to <i<ESR1</i< increased gene dosage, high <i<ERα36</i< expression was linked with the decreased disease-free survival of the patients (<i<p</i< = 0.05), which was independent of the status of the classical <i<ERα66</i< level in breast tumors.
650		4	\|a breast cancer
650		4	\|a estrogen receptor
650		4	\|a ERα36, ERα66, gene amplification
650		4	\|a prognostic factor
653		0	\|a Biology (General)
653		0	\|a Chemistry
700	0		\|a Jolanta Szade \|e verfasserin \|4 aut
700	0		\|a Mariola Iliszko \|e verfasserin \|4 aut
700	0		\|a Julia Elzanowska \|e verfasserin \|4 aut
700	0		\|a Marzena Welnicka-Jaskiewicz \|e verfasserin \|4 aut
700	0		\|a Jaroslaw Skokowski \|e verfasserin \|4 aut
700	0		\|a Grzegorz Stasilojc \|e verfasserin \|4 aut
700	0		\|a Jacek Bigda \|e verfasserin \|4 aut
700	0		\|a Rafal Sadej \|e verfasserin \|4 aut
700	0		\|a Anna Zaczek \|e verfasserin \|4 aut
700	0		\|a Aleksandra Markiewicz \|e verfasserin \|4 aut
773	0	8	\|i In \|t International Journal of Molecular Sciences \|d MDPI AG, 2003 \|g 20(2019), 8, p 1881 \|w (DE-627)316340715 \|w (DE-600)2019364-6 \|x 14220067 \|7 nnns
773	1	8	\|g volume:20 \|g year:2019 \|g number:8, p 1881
856	4	0	\|u https://doi.org/10.3390/ijms20081881 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/366d1ba6c63f4fc5a4a15f556e226d90 \|z kostenfrei
856	4	0	\|u https://www.mdpi.com/1422-0067/20/8/1881 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1422-0067 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_224
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 20 \|j 2019 \|e 8, p 1881

Indexfelder

author_variant	a n an j s js m i mi j e je m w j mwj j s js g s gs j b jb r s rs a z az a m am
matchkey_str	article:14220067:2019----::lnclnbooiasgiiacois1gnatrtoadsrgneetrioome
hierarchy_sort_str	2019
callnumber-subject-code	QH
publishDate	2019
allfields	10.3390/ijms20081881 doi (DE-627)DOAJ045603391 (DE-599)DOAJ366d1ba6c63f4fc5a4a15f556e226d90 DE-627 ger DE-627 rakwb eng QH301-705.5 QD1-999 Anna Nagel verfasserin aut Clinical and Biological Significance of <i<ESR1</i< Gene Alteration and Estrogen Receptors Isoforms Expression in Breast Cancer Patients 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The amplification of estrogen receptor alpha (ERα) encoded by the <i<ESR1</i< gene has been described as having a prognostic role in breast cancer patients. However, increased dosage of the <i<ESR1</i< gene (tested by real-time PCR) is also observed in ER-negative breast cancers, which might suggest the expression of alternative isoforms of ERα (other than classical ERα of 66 kDa). In the current work, we have investigated the <i<ESR1</i< gene dosage in 402 primary breast cancer patients as well as the expression of ERα isoforms—ERα66 and ERα36—on mRNA and protein levels. The obtained results were correlated with clinicopathological data of the patients. Results showed that increased <i<ESR1</i< gene dosage is not related to <i<ESR1</i< gene amplification measured by fluorescent in situ hybridization (FISH), but it correlates with the decreased expression of <i<ERα66</i< isoform (<i<p</i< = 0.01). Interestingly, the short ER isoform <i<ERα36</i< was expressed in samples with increased <i<ESR1</i< gene dosage, suggesting that genomic aberration might influence the expression of that particular isoform. Similarly to <i<ESR1</i< increased gene dosage, high <i<ERα36</i< expression was linked with the decreased disease-free survival of the patients (<i<p</i< = 0.05), which was independent of the status of the classical <i<ERα66</i< level in breast tumors. breast cancer estrogen receptor ERα36, ERα66, gene amplification prognostic factor Biology (General) Chemistry Jolanta Szade verfasserin aut Mariola Iliszko verfasserin aut Julia Elzanowska verfasserin aut Marzena Welnicka-Jaskiewicz verfasserin aut Jaroslaw Skokowski verfasserin aut Grzegorz Stasilojc verfasserin aut Jacek Bigda verfasserin aut Rafal Sadej verfasserin aut Anna Zaczek verfasserin aut Aleksandra Markiewicz verfasserin aut In International Journal of Molecular Sciences MDPI AG, 2003 20(2019), 8, p 1881 (DE-627)316340715 (DE-600)2019364-6 14220067 nnns volume:20 year:2019 number:8, p 1881 https://doi.org/10.3390/ijms20081881 kostenfrei https://doaj.org/article/366d1ba6c63f4fc5a4a15f556e226d90 kostenfrei https://www.mdpi.com/1422-0067/20/8/1881 kostenfrei https://doaj.org/toc/1422-0067 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 20 2019 8, p 1881
spelling	10.3390/ijms20081881 doi (DE-627)DOAJ045603391 (DE-599)DOAJ366d1ba6c63f4fc5a4a15f556e226d90 DE-627 ger DE-627 rakwb eng QH301-705.5 QD1-999 Anna Nagel verfasserin aut Clinical and Biological Significance of <i<ESR1</i< Gene Alteration and Estrogen Receptors Isoforms Expression in Breast Cancer Patients 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The amplification of estrogen receptor alpha (ERα) encoded by the <i<ESR1</i< gene has been described as having a prognostic role in breast cancer patients. However, increased dosage of the <i<ESR1</i< gene (tested by real-time PCR) is also observed in ER-negative breast cancers, which might suggest the expression of alternative isoforms of ERα (other than classical ERα of 66 kDa). In the current work, we have investigated the <i<ESR1</i< gene dosage in 402 primary breast cancer patients as well as the expression of ERα isoforms—ERα66 and ERα36—on mRNA and protein levels. The obtained results were correlated with clinicopathological data of the patients. Results showed that increased <i<ESR1</i< gene dosage is not related to <i<ESR1</i< gene amplification measured by fluorescent in situ hybridization (FISH), but it correlates with the decreased expression of <i<ERα66</i< isoform (<i<p</i< = 0.01). Interestingly, the short ER isoform <i<ERα36</i< was expressed in samples with increased <i<ESR1</i< gene dosage, suggesting that genomic aberration might influence the expression of that particular isoform. Similarly to <i<ESR1</i< increased gene dosage, high <i<ERα36</i< expression was linked with the decreased disease-free survival of the patients (<i<p</i< = 0.05), which was independent of the status of the classical <i<ERα66</i< level in breast tumors. breast cancer estrogen receptor ERα36, ERα66, gene amplification prognostic factor Biology (General) Chemistry Jolanta Szade verfasserin aut Mariola Iliszko verfasserin aut Julia Elzanowska verfasserin aut Marzena Welnicka-Jaskiewicz verfasserin aut Jaroslaw Skokowski verfasserin aut Grzegorz Stasilojc verfasserin aut Jacek Bigda verfasserin aut Rafal Sadej verfasserin aut Anna Zaczek verfasserin aut Aleksandra Markiewicz verfasserin aut In International Journal of Molecular Sciences MDPI AG, 2003 20(2019), 8, p 1881 (DE-627)316340715 (DE-600)2019364-6 14220067 nnns volume:20 year:2019 number:8, p 1881 https://doi.org/10.3390/ijms20081881 kostenfrei https://doaj.org/article/366d1ba6c63f4fc5a4a15f556e226d90 kostenfrei https://www.mdpi.com/1422-0067/20/8/1881 kostenfrei https://doaj.org/toc/1422-0067 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 20 2019 8, p 1881
allfields_unstemmed	10.3390/ijms20081881 doi (DE-627)DOAJ045603391 (DE-599)DOAJ366d1ba6c63f4fc5a4a15f556e226d90 DE-627 ger DE-627 rakwb eng QH301-705.5 QD1-999 Anna Nagel verfasserin aut Clinical and Biological Significance of <i<ESR1</i< Gene Alteration and Estrogen Receptors Isoforms Expression in Breast Cancer Patients 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The amplification of estrogen receptor alpha (ERα) encoded by the <i<ESR1</i< gene has been described as having a prognostic role in breast cancer patients. However, increased dosage of the <i<ESR1</i< gene (tested by real-time PCR) is also observed in ER-negative breast cancers, which might suggest the expression of alternative isoforms of ERα (other than classical ERα of 66 kDa). In the current work, we have investigated the <i<ESR1</i< gene dosage in 402 primary breast cancer patients as well as the expression of ERα isoforms—ERα66 and ERα36—on mRNA and protein levels. The obtained results were correlated with clinicopathological data of the patients. Results showed that increased <i<ESR1</i< gene dosage is not related to <i<ESR1</i< gene amplification measured by fluorescent in situ hybridization (FISH), but it correlates with the decreased expression of <i<ERα66</i< isoform (<i<p</i< = 0.01). Interestingly, the short ER isoform <i<ERα36</i< was expressed in samples with increased <i<ESR1</i< gene dosage, suggesting that genomic aberration might influence the expression of that particular isoform. Similarly to <i<ESR1</i< increased gene dosage, high <i<ERα36</i< expression was linked with the decreased disease-free survival of the patients (<i<p</i< = 0.05), which was independent of the status of the classical <i<ERα66</i< level in breast tumors. breast cancer estrogen receptor ERα36, ERα66, gene amplification prognostic factor Biology (General) Chemistry Jolanta Szade verfasserin aut Mariola Iliszko verfasserin aut Julia Elzanowska verfasserin aut Marzena Welnicka-Jaskiewicz verfasserin aut Jaroslaw Skokowski verfasserin aut Grzegorz Stasilojc verfasserin aut Jacek Bigda verfasserin aut Rafal Sadej verfasserin aut Anna Zaczek verfasserin aut Aleksandra Markiewicz verfasserin aut In International Journal of Molecular Sciences MDPI AG, 2003 20(2019), 8, p 1881 (DE-627)316340715 (DE-600)2019364-6 14220067 nnns volume:20 year:2019 number:8, p 1881 https://doi.org/10.3390/ijms20081881 kostenfrei https://doaj.org/article/366d1ba6c63f4fc5a4a15f556e226d90 kostenfrei https://www.mdpi.com/1422-0067/20/8/1881 kostenfrei https://doaj.org/toc/1422-0067 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 20 2019 8, p 1881
allfieldsGer	10.3390/ijms20081881 doi (DE-627)DOAJ045603391 (DE-599)DOAJ366d1ba6c63f4fc5a4a15f556e226d90 DE-627 ger DE-627 rakwb eng QH301-705.5 QD1-999 Anna Nagel verfasserin aut Clinical and Biological Significance of <i<ESR1</i< Gene Alteration and Estrogen Receptors Isoforms Expression in Breast Cancer Patients 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The amplification of estrogen receptor alpha (ERα) encoded by the <i<ESR1</i< gene has been described as having a prognostic role in breast cancer patients. However, increased dosage of the <i<ESR1</i< gene (tested by real-time PCR) is also observed in ER-negative breast cancers, which might suggest the expression of alternative isoforms of ERα (other than classical ERα of 66 kDa). In the current work, we have investigated the <i<ESR1</i< gene dosage in 402 primary breast cancer patients as well as the expression of ERα isoforms—ERα66 and ERα36—on mRNA and protein levels. The obtained results were correlated with clinicopathological data of the patients. Results showed that increased <i<ESR1</i< gene dosage is not related to <i<ESR1</i< gene amplification measured by fluorescent in situ hybridization (FISH), but it correlates with the decreased expression of <i<ERα66</i< isoform (<i<p</i< = 0.01). Interestingly, the short ER isoform <i<ERα36</i< was expressed in samples with increased <i<ESR1</i< gene dosage, suggesting that genomic aberration might influence the expression of that particular isoform. Similarly to <i<ESR1</i< increased gene dosage, high <i<ERα36</i< expression was linked with the decreased disease-free survival of the patients (<i<p</i< = 0.05), which was independent of the status of the classical <i<ERα66</i< level in breast tumors. breast cancer estrogen receptor ERα36, ERα66, gene amplification prognostic factor Biology (General) Chemistry Jolanta Szade verfasserin aut Mariola Iliszko verfasserin aut Julia Elzanowska verfasserin aut Marzena Welnicka-Jaskiewicz verfasserin aut Jaroslaw Skokowski verfasserin aut Grzegorz Stasilojc verfasserin aut Jacek Bigda verfasserin aut Rafal Sadej verfasserin aut Anna Zaczek verfasserin aut Aleksandra Markiewicz verfasserin aut In International Journal of Molecular Sciences MDPI AG, 2003 20(2019), 8, p 1881 (DE-627)316340715 (DE-600)2019364-6 14220067 nnns volume:20 year:2019 number:8, p 1881 https://doi.org/10.3390/ijms20081881 kostenfrei https://doaj.org/article/366d1ba6c63f4fc5a4a15f556e226d90 kostenfrei https://www.mdpi.com/1422-0067/20/8/1881 kostenfrei https://doaj.org/toc/1422-0067 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 20 2019 8, p 1881
allfieldsSound	10.3390/ijms20081881 doi (DE-627)DOAJ045603391 (DE-599)DOAJ366d1ba6c63f4fc5a4a15f556e226d90 DE-627 ger DE-627 rakwb eng QH301-705.5 QD1-999 Anna Nagel verfasserin aut Clinical and Biological Significance of <i<ESR1</i< Gene Alteration and Estrogen Receptors Isoforms Expression in Breast Cancer Patients 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The amplification of estrogen receptor alpha (ERα) encoded by the <i<ESR1</i< gene has been described as having a prognostic role in breast cancer patients. However, increased dosage of the <i<ESR1</i< gene (tested by real-time PCR) is also observed in ER-negative breast cancers, which might suggest the expression of alternative isoforms of ERα (other than classical ERα of 66 kDa). In the current work, we have investigated the <i<ESR1</i< gene dosage in 402 primary breast cancer patients as well as the expression of ERα isoforms—ERα66 and ERα36—on mRNA and protein levels. The obtained results were correlated with clinicopathological data of the patients. Results showed that increased <i<ESR1</i< gene dosage is not related to <i<ESR1</i< gene amplification measured by fluorescent in situ hybridization (FISH), but it correlates with the decreased expression of <i<ERα66</i< isoform (<i<p</i< = 0.01). Interestingly, the short ER isoform <i<ERα36</i< was expressed in samples with increased <i<ESR1</i< gene dosage, suggesting that genomic aberration might influence the expression of that particular isoform. Similarly to <i<ESR1</i< increased gene dosage, high <i<ERα36</i< expression was linked with the decreased disease-free survival of the patients (<i<p</i< = 0.05), which was independent of the status of the classical <i<ERα66</i< level in breast tumors. breast cancer estrogen receptor ERα36, ERα66, gene amplification prognostic factor Biology (General) Chemistry Jolanta Szade verfasserin aut Mariola Iliszko verfasserin aut Julia Elzanowska verfasserin aut Marzena Welnicka-Jaskiewicz verfasserin aut Jaroslaw Skokowski verfasserin aut Grzegorz Stasilojc verfasserin aut Jacek Bigda verfasserin aut Rafal Sadej verfasserin aut Anna Zaczek verfasserin aut Aleksandra Markiewicz verfasserin aut In International Journal of Molecular Sciences MDPI AG, 2003 20(2019), 8, p 1881 (DE-627)316340715 (DE-600)2019364-6 14220067 nnns volume:20 year:2019 number:8, p 1881 https://doi.org/10.3390/ijms20081881 kostenfrei https://doaj.org/article/366d1ba6c63f4fc5a4a15f556e226d90 kostenfrei https://www.mdpi.com/1422-0067/20/8/1881 kostenfrei https://doaj.org/toc/1422-0067 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 20 2019 8, p 1881
language	English
source	In International Journal of Molecular Sciences 20(2019), 8, p 1881 volume:20 year:2019 number:8, p 1881
sourceStr	In International Journal of Molecular Sciences 20(2019), 8, p 1881 volume:20 year:2019 number:8, p 1881
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	breast cancer estrogen receptor ERα36, ERα66, gene amplification prognostic factor Biology (General) Chemistry
isfreeaccess_bool	true
container_title	International Journal of Molecular Sciences
authorswithroles_txt_mv	Anna Nagel @@aut@@ Jolanta Szade @@aut@@ Mariola Iliszko @@aut@@ Julia Elzanowska @@aut@@ Marzena Welnicka-Jaskiewicz @@aut@@ Jaroslaw Skokowski @@aut@@ Grzegorz Stasilojc @@aut@@ Jacek Bigda @@aut@@ Rafal Sadej @@aut@@ Anna Zaczek @@aut@@ Aleksandra Markiewicz @@aut@@
publishDateDaySort_date	2019-01-01T00:00:00Z
hierarchy_top_id	316340715
id	DOAJ045603391
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ045603391</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308093747.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2019 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/ijms20081881</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ045603391</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ366d1ba6c63f4fc5a4a15f556e226d90</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QH301-705.5</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QD1-999</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Anna Nagel</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Clinical and Biological Significance of <i<ESR1</i< Gene Alteration and Estrogen Receptors Isoforms Expression in Breast Cancer Patients</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The amplification of estrogen receptor alpha (ERα) encoded by the <i<ESR1</i< gene has been described as having a prognostic role in breast cancer patients. However, increased dosage of the <i<ESR1</i< gene (tested by real-time PCR) is also observed in ER-negative breast cancers, which might suggest the expression of alternative isoforms of ERα (other than classical ERα of 66 kDa). In the current work, we have investigated the <i<ESR1</i< gene dosage in 402 primary breast cancer patients as well as the expression of ERα isoforms—ERα66 and ERα36—on mRNA and protein levels. The obtained results were correlated with clinicopathological data of the patients. Results showed that increased <i<ESR1</i< gene dosage is not related to <i<ESR1</i< gene amplification measured by fluorescent in situ hybridization (FISH), but it correlates with the decreased expression of <i<ERα66</i< isoform (<i<p</i< = 0.01). Interestingly, the short ER isoform <i<ERα36</i< was expressed in samples with increased <i<ESR1</i< gene dosage, suggesting that genomic aberration might influence the expression of that particular isoform. Similarly to <i<ESR1</i< increased gene dosage, high <i<ERα36</i< expression was linked with the decreased disease-free survival of the patients (<i<p</i< = 0.05), which was independent of the status of the classical <i<ERα66</i< level in breast tumors.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">breast cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">estrogen receptor</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ERα36, ERα66, gene amplification</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">prognostic factor</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Biology (General)</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Chemistry</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jolanta Szade</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mariola Iliszko</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Julia Elzanowska</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Marzena Welnicka-Jaskiewicz</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jaroslaw Skokowski</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Grzegorz Stasilojc</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jacek Bigda</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Rafal Sadej</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Anna Zaczek</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Aleksandra Markiewicz</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">International Journal of Molecular Sciences</subfield><subfield code="d">MDPI AG, 2003</subfield><subfield code="g">20(2019), 8, p 1881</subfield><subfield code="w">(DE-627)316340715</subfield><subfield code="w">(DE-600)2019364-6</subfield><subfield code="x">14220067</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:20</subfield><subfield code="g">year:2019</subfield><subfield code="g">number:8, p 1881</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/ijms20081881</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/366d1ba6c63f4fc5a4a15f556e226d90</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/1422-0067/20/8/1881</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1422-0067</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">20</subfield><subfield code="j">2019</subfield><subfield code="e">8, p 1881</subfield></datafield></record></collection>
callnumber-first	Q - Science
author	Anna Nagel
spellingShingle	Anna Nagel misc QH301-705.5 misc QD1-999 misc breast cancer misc estrogen receptor misc ERα36, ERα66, gene amplification misc prognostic factor misc Biology (General) misc Chemistry Clinical and Biological Significance of <i<ESR1</i< Gene Alteration and Estrogen Receptors Isoforms Expression in Breast Cancer Patients
authorStr	Anna Nagel
ppnlink_with_tag_str_mv	@@773@@(DE-627)316340715
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	QH301-705
illustrated	Not Illustrated
issn	14220067
topic_title	QH301-705.5 QD1-999 Clinical and Biological Significance of <i<ESR1</i< Gene Alteration and Estrogen Receptors Isoforms Expression in Breast Cancer Patients breast cancer estrogen receptor ERα36, ERα66, gene amplification prognostic factor
topic	misc QH301-705.5 misc QD1-999 misc breast cancer misc estrogen receptor misc ERα36, ERα66, gene amplification misc prognostic factor misc Biology (General) misc Chemistry
topic_unstemmed	misc QH301-705.5 misc QD1-999 misc breast cancer misc estrogen receptor misc ERα36, ERα66, gene amplification misc prognostic factor misc Biology (General) misc Chemistry
topic_browse	misc QH301-705.5 misc QD1-999 misc breast cancer misc estrogen receptor misc ERα36, ERα66, gene amplification misc prognostic factor misc Biology (General) misc Chemistry
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	International Journal of Molecular Sciences
hierarchy_parent_id	316340715
hierarchy_top_title	International Journal of Molecular Sciences
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)316340715 (DE-600)2019364-6
title	Clinical and Biological Significance of <i<ESR1</i< Gene Alteration and Estrogen Receptors Isoforms Expression in Breast Cancer Patients
ctrlnum	(DE-627)DOAJ045603391 (DE-599)DOAJ366d1ba6c63f4fc5a4a15f556e226d90
title_full	Clinical and Biological Significance of <i<ESR1</i< Gene Alteration and Estrogen Receptors Isoforms Expression in Breast Cancer Patients
author_sort	Anna Nagel
journal	International Journal of Molecular Sciences
journalStr	International Journal of Molecular Sciences
callnumber-first-code	Q
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2019
contenttype_str_mv	txt
author_browse	Anna Nagel Jolanta Szade Mariola Iliszko Julia Elzanowska Marzena Welnicka-Jaskiewicz Jaroslaw Skokowski Grzegorz Stasilojc Jacek Bigda Rafal Sadej Anna Zaczek Aleksandra Markiewicz
container_volume	20
class	QH301-705.5 QD1-999
format_se	Elektronische Aufsätze
author-letter	Anna Nagel
doi_str_mv	10.3390/ijms20081881
author2-role	verfasserin
title_sort	clinical and biological significance of <i<esr1</i< gene alteration and estrogen receptors isoforms expression in breast cancer patients
callnumber	QH301-705.5
title_auth	Clinical and Biological Significance of <i<ESR1</i< Gene Alteration and Estrogen Receptors Isoforms Expression in Breast Cancer Patients
abstract	The amplification of estrogen receptor alpha (ERα) encoded by the <i<ESR1</i< gene has been described as having a prognostic role in breast cancer patients. However, increased dosage of the <i<ESR1</i< gene (tested by real-time PCR) is also observed in ER-negative breast cancers, which might suggest the expression of alternative isoforms of ERα (other than classical ERα of 66 kDa). In the current work, we have investigated the <i<ESR1</i< gene dosage in 402 primary breast cancer patients as well as the expression of ERα isoforms—ERα66 and ERα36—on mRNA and protein levels. The obtained results were correlated with clinicopathological data of the patients. Results showed that increased <i<ESR1</i< gene dosage is not related to <i<ESR1</i< gene amplification measured by fluorescent in situ hybridization (FISH), but it correlates with the decreased expression of <i<ERα66</i< isoform (<i<p</i< = 0.01). Interestingly, the short ER isoform <i<ERα36</i< was expressed in samples with increased <i<ESR1</i< gene dosage, suggesting that genomic aberration might influence the expression of that particular isoform. Similarly to <i<ESR1</i< increased gene dosage, high <i<ERα36</i< expression was linked with the decreased disease-free survival of the patients (<i<p</i< = 0.05), which was independent of the status of the classical <i<ERα66</i< level in breast tumors.
abstractGer	The amplification of estrogen receptor alpha (ERα) encoded by the <i<ESR1</i< gene has been described as having a prognostic role in breast cancer patients. However, increased dosage of the <i<ESR1</i< gene (tested by real-time PCR) is also observed in ER-negative breast cancers, which might suggest the expression of alternative isoforms of ERα (other than classical ERα of 66 kDa). In the current work, we have investigated the <i<ESR1</i< gene dosage in 402 primary breast cancer patients as well as the expression of ERα isoforms—ERα66 and ERα36—on mRNA and protein levels. The obtained results were correlated with clinicopathological data of the patients. Results showed that increased <i<ESR1</i< gene dosage is not related to <i<ESR1</i< gene amplification measured by fluorescent in situ hybridization (FISH), but it correlates with the decreased expression of <i<ERα66</i< isoform (<i<p</i< = 0.01). Interestingly, the short ER isoform <i<ERα36</i< was expressed in samples with increased <i<ESR1</i< gene dosage, suggesting that genomic aberration might influence the expression of that particular isoform. Similarly to <i<ESR1</i< increased gene dosage, high <i<ERα36</i< expression was linked with the decreased disease-free survival of the patients (<i<p</i< = 0.05), which was independent of the status of the classical <i<ERα66</i< level in breast tumors.
abstract_unstemmed	The amplification of estrogen receptor alpha (ERα) encoded by the <i<ESR1</i< gene has been described as having a prognostic role in breast cancer patients. However, increased dosage of the <i<ESR1</i< gene (tested by real-time PCR) is also observed in ER-negative breast cancers, which might suggest the expression of alternative isoforms of ERα (other than classical ERα of 66 kDa). In the current work, we have investigated the <i<ESR1</i< gene dosage in 402 primary breast cancer patients as well as the expression of ERα isoforms—ERα66 and ERα36—on mRNA and protein levels. The obtained results were correlated with clinicopathological data of the patients. Results showed that increased <i<ESR1</i< gene dosage is not related to <i<ESR1</i< gene amplification measured by fluorescent in situ hybridization (FISH), but it correlates with the decreased expression of <i<ERα66</i< isoform (<i<p</i< = 0.01). Interestingly, the short ER isoform <i<ERα36</i< was expressed in samples with increased <i<ESR1</i< gene dosage, suggesting that genomic aberration might influence the expression of that particular isoform. Similarly to <i<ESR1</i< increased gene dosage, high <i<ERα36</i< expression was linked with the decreased disease-free survival of the patients (<i<p</i< = 0.05), which was independent of the status of the classical <i<ERα66</i< level in breast tumors.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	8, p 1881
title_short	Clinical and Biological Significance of <i<ESR1</i< Gene Alteration and Estrogen Receptors Isoforms Expression in Breast Cancer Patients
url	https://doi.org/10.3390/ijms20081881 https://doaj.org/article/366d1ba6c63f4fc5a4a15f556e226d90 https://www.mdpi.com/1422-0067/20/8/1881 https://doaj.org/toc/1422-0067
remote_bool	true
author2	Jolanta Szade Mariola Iliszko Julia Elzanowska Marzena Welnicka-Jaskiewicz Jaroslaw Skokowski Grzegorz Stasilojc Jacek Bigda Rafal Sadej Anna Zaczek Aleksandra Markiewicz
author2Str	Jolanta Szade Mariola Iliszko Julia Elzanowska Marzena Welnicka-Jaskiewicz Jaroslaw Skokowski Grzegorz Stasilojc Jacek Bigda Rafal Sadej Anna Zaczek Aleksandra Markiewicz
ppnlink	316340715
callnumber-subject	QH - Natural History and Biology
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.3390/ijms20081881
callnumber-a	QH301-705.5
up_date	2024-07-03T15:55:05.442Z
_version_	1803573899241193472
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ045603391</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308093747.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2019 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/ijms20081881</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ045603391</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ366d1ba6c63f4fc5a4a15f556e226d90</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QH301-705.5</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QD1-999</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Anna Nagel</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Clinical and Biological Significance of <i<ESR1</i< Gene Alteration and Estrogen Receptors Isoforms Expression in Breast Cancer Patients</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The amplification of estrogen receptor alpha (ERα) encoded by the <i<ESR1</i< gene has been described as having a prognostic role in breast cancer patients. However, increased dosage of the <i<ESR1</i< gene (tested by real-time PCR) is also observed in ER-negative breast cancers, which might suggest the expression of alternative isoforms of ERα (other than classical ERα of 66 kDa). In the current work, we have investigated the <i<ESR1</i< gene dosage in 402 primary breast cancer patients as well as the expression of ERα isoforms—ERα66 and ERα36—on mRNA and protein levels. The obtained results were correlated with clinicopathological data of the patients. Results showed that increased <i<ESR1</i< gene dosage is not related to <i<ESR1</i< gene amplification measured by fluorescent in situ hybridization (FISH), but it correlates with the decreased expression of <i<ERα66</i< isoform (<i<p</i< = 0.01). Interestingly, the short ER isoform <i<ERα36</i< was expressed in samples with increased <i<ESR1</i< gene dosage, suggesting that genomic aberration might influence the expression of that particular isoform. Similarly to <i<ESR1</i< increased gene dosage, high <i<ERα36</i< expression was linked with the decreased disease-free survival of the patients (<i<p</i< = 0.05), which was independent of the status of the classical <i<ERα66</i< level in breast tumors.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">breast cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">estrogen receptor</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ERα36, ERα66, gene amplification</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">prognostic factor</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Biology (General)</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Chemistry</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jolanta Szade</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mariola Iliszko</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Julia Elzanowska</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Marzena Welnicka-Jaskiewicz</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jaroslaw Skokowski</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Grzegorz Stasilojc</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jacek Bigda</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Rafal Sadej</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Anna Zaczek</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Aleksandra Markiewicz</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">International Journal of Molecular Sciences</subfield><subfield code="d">MDPI AG, 2003</subfield><subfield code="g">20(2019), 8, p 1881</subfield><subfield code="w">(DE-627)316340715</subfield><subfield code="w">(DE-600)2019364-6</subfield><subfield code="x">14220067</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:20</subfield><subfield code="g">year:2019</subfield><subfield code="g">number:8, p 1881</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/ijms20081881</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/366d1ba6c63f4fc5a4a15f556e226d90</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/1422-0067/20/8/1881</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1422-0067</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">20</subfield><subfield code="j">2019</subfield><subfield code="e">8, p 1881</subfield></datafield></record></collection>
score	7.4012766

Nicht das Richtige dabei?

Schreiben Sie uns!

Clinical and Biological Significance of <i<ESR1</i< Gene Alteration and Estrogen Receptors Isoforms Expression in Breast Cancer Patients

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?